Cuba's second Covid-19 vaccine Soberana 2 boasts 91.2% efficacy in late-stage trials

Cuba's biotech sector has a long history of vaccine development, producing 80 per cent of vaccines used in the country and exporting some of them. PHOTO: AFP

HAVANA (REUTERS) - Cuba said on Thursday (July 8) its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2 per cent effective in late-stage clinical trials against the coronavirus, following similar news about its Abdala vaccine.

The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees the Finlay Institute, the maker of Soberana 2, and the Centre for Genetic Engineering and Biotechnology, the producer of Abdala.

Last month, Abdala was found to have a 92.28 per cent efficacy.

While the Cuban efficacy claims have not been peer-reviewed, the results, if accurate, would catapult the US-boycotted Caribbean island nation into the select group of the United States, Germany and Russia that produce vaccines with efficacy of more than 90 per cent - Novavax, Pfizer-BioNTech, Moderna and Sputnik V.

Cuba's biotech sector has a long history of vaccine development, producing 80 per cent of vaccines used in the country and exporting some of them.

Communist-run Cuba is the first country in Latin America and the Caribbean to successfully develop a coronavirus vaccine.

The import-dependent island is in the throes of an economic crisis, with activity falling 10.9 per cent last year and 2 per cent the first half of 2021 as the pandemic kept the tourism industry shuttered and Donald Trump-era sanctions on top of the decades-old trade embargo hammered finance and trade.

Cuba says it has a total of five candidate vaccines in the pipeline, with Abdala and Soberana 2 expected to be quickly authorised for emergency use by local regulators and sent up for approval to the World Health Organisation.

The local authorisations would open the way for other countries to purchase the vaccines or produce them. Mexico, Argentina and Vietnam have expressed interest in production and Iran says it is producing Soberana 2 after trials in that country.

Both vaccines are "low" tech, meaning they use a traditional approach to build up the immune system by deploying a part of the virus' spike protein that helps the virus enter and infect cells.

These vaccines are generally less expensive to develop and easier to store and transport as they do not require extremely low temperatures.

The three-shot Abdala, named after a poem by apostle Jose Marti, is given in two-week intervals, while Soberana 2, translated as "sovereign" in English, is administered in four-week intervals.

Following the arrival of more contagious variants, Cuba is facing its worst Covid-19 outbreak since the start of the pandemic, setting new records for daily coronavirus cases at more than 3,500 this week.

The authorities have already started administering the up-to-now experimental vaccines en masse as part of "intervention studies" they hope will slow the spread of the virus.

About 1.5 million of the country's 11.2 million residents have been fully vaccinated to date.

As at Wednesday, Cuba has reported a total of 218,376 Covid-19 cases and 1,431 deaths.

Join ST's Telegram channel here and get the latest breaking news delivered to you.